On Friday, Amarantus BioSciences Inc (OTC:AMBS) seen an upswing after the Company announced Mr. Gerald Commissiong, the co founder to replace Martin D. Cleary as the President & Chief Executive Officer.
Mr. Commissiong had co-founded Amarantus with Dr. John Commissiong in 2008 and had been serving the Company as a Chief Business Officer and later as a Chief Operating Officer since then. During his tenure as a Chief Officer he had attracted seed capital, acquired the intellectual property rights to MANF, and recruited scientific and executive talent to Amarantus.
The Company’s drug candidate- MANF- is a protein that corrects protein misfolding, cited as a major cause of apoptosis. The MANF is being developed for treatment of Parkinson’s disease as it can be applied as a first-in-class disease–modifying therapeutic protein that mitigates an underlying cause of cell death.
Amarantus had on October 20, 2011 announced that it has received a Notice of Allowance from the United States Patent & Trademark Office granting the Company the claims to the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF). The patent also includes compositions of matter and methods of use for MANF, and other related compounds.
Shares of Amarantus BioSciences Inc (OTC:AMBS) has soared about 70%, since the acquisition of IPR for MANF and the appointment of Mr. Commissiong as President & Chief Executive Officer made its shares bounce 30% or $0.045. 151.43 shares traded hands which is 12 times its average trading volume of 11.761K shares. The stock has jumped 63% in the past couple of trading sessions.
Amarantus BioSciences, Inc., formerly Jumpkicks, Inc., is a development-stage biotechnology company. The Company focuses on developing its intellectual property and technology to develop drug candidates to treat human disease.
Disclaimer:
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.
